mRNA Therapeutics CDMO Market Revenue to Attain USD 12 Bn by 2033

11 Jun 2025

Share :

Table of Content

1. mRNA Therapeutics CDMO Market Revenue and Trends 2025 to 2033 2. Unlocking Growth: The Future of the mRNA Therapeutics CDMO Market 3. Regional Insights 4. mRNA Therapeutics CDMO Market Coverage 5. mRNA Therapeutics CDMO Market Companies

mRNA Therapeutics CDMO Market Revenue and Trends 2025 to 2033

The global mRNA therapeutics CDMO market revenue surpassed USD 5.09 billion in 2025 and is predicted to attain around USD 12 billion by 2033, growing at a CAGR of 11.32%. The rising production of mRNA vaccines for infectious disease boosts the market growth.

Unlocking Growth: The Future of the mRNA Therapeutics CDMO Market

The market is rapidly expanding, fueled by the rising demand for personalized medicine. The success of mRNA COVID-19 vaccines highlights the potential of mRNA in treating infectious diseases. A growing pipeline of mRNA therapies and vaccines for various diseases drives the need for specialized CDMO services with mRNA capabilities and infrastructure. Companies increasingly rely on CDMOs for scaling R&D and clinical production, accelerating time to market. Government and private investment in mRNA technology, along with advancements in LNP delivery systems, further boosts the market. Streamlined regulatory pathways also support innovation and scalability.

Segment Insights

• By application, the viral vaccines segment dominated the market in 2024. This is mainly due to the increased pipeline of mRNA vaccines for viral infections. mRNA technology is suitable for rapid vaccine production.
• By indication, the infectious diseases segment led the market with the largest share in 2024. The significant rise in the prevalence of infectious diseases has prompted the need for effective therapeutics. This significantly boostes investment in mRNA technology as it has proven effective in preventing and controlling infectious diseases.
• The biotech companies segment dominated the market in 2024. Since these companies actively engage in R&D and vaccine production, they rely on CDMO to boost their production capabilities. Outsourcing production to CDMOs enable biotech companies to focus on other core competencies.

Regional Insights

North America is the leading region in the mRNA therapeutics CDMO market, propelled by its strong research and development infrastructure and early uptake for mRNA technologies. The strong presence of major biotech players and CDMOs strengthens the region's position in the market. The rising demand for personalized medicine as a result of increased prevalence of genetic diseases further bolsters the market growth within the region.

Asia Pacific is expected to experience the fastest growth during the forecast period. The growth of the market in the region is attributed to the rising prevalence of infectious diseases, high demand for mRNA-based therapies, and increasing number of clinical teials. The rising development of novel vaccines creates immense opportunities in the market within the region.

mRNA Therapeutics CDMO Market Coverage

Recent Development

• In May 2024, BioNTech received a USD 145 million in funding build a production network in Africa for shots based on cutting-edge messenger-RNA (mRNA) technology. (Sources- https://www.reuters.com)

mRNA Therapeutics CDMO Market Companies

• Danaher (Aldevron)
• Biomay AG
• Bio-Synthesis, Inc.
• eTheRNA
• Kaneka Eurogentec S.A.
• TriLink BioTechnologies
• ApexBio Technology
• BioNTech SE
• Biocina
• Lonza
• Recipharm AB
• Novo Holdings (Catalent, Inc.)
• Samsung Biologics

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6199

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com|+1 804 441 9344